{"id":"W2762414010","doi":"10.1093/annonc/mdx370.011","title":"EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 update on safety, tolerability, pharmacokinetics and efficacy","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Enzalutamide; Prostate cancer; Pharmacokinetics; Cmax; Adverse effect; Internal medicine; Abiraterone acetate; Gastroenterology; Phases of clinical research; Urology; Nausea; Pharmacology; Oncology; Cancer; Chemotherapy; Androgen deprivation therapy; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005846895,0.0004114733,0.00103733,0.0003860522,0.0001020976,0.0004297426,0.0004391732,0.0002935262,0.001715986],"category_scores_gemma":[0.0006303969,0.0001727729,0.0004864698,0.0004103514,0.0002260659,0.0003497262,0.0001913765,0.001152341,0.0005882967],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002981321,"about_ca_system_score_gemma":0.0003628921,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009750563,"about_ca_topic_score_gemma":0.004907748,"domain_scores_codex":[0.999858,0.00003740003,0.00001498058,0.00001872103,0.00005275819,0.00001802213],"domain_scores_gemma":[0.9997489,0.00009434969,0.00006997245,0.00001279236,0.00003430323,0.0000397187],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01025305,0.001041755,0.00480555,0.002758831,0.0008589459,0.0003181878,0.0001038077,0.002546195,0.05193213,0.0007760326,0.01491498,0.9096906],"study_design_scores_gemma":[0.05292692,0.119521,0.1355718,0.002145929,0.005552212,0.01841456,0.0003506729,0.01178128,0.1033336,0.003355989,0.5466699,0.0003763427],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.4791703,0.4811359,0.006143266,0.002959667,0.0005307663,0.0006036098,0.005054099,0.001396588,0.02300593],"genre_scores_gemma":[0.755275,0.2170392,0.007559516,0.003744136,0.0003634111,0.0002672034,0.008083628,0.0001117906,0.007556232],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.001715986,"threshold_uncertainty_score":0.005740523,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08809003921003584,"score_gpt":0.4383077206600831,"score_spread":0.3502176814500472,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}